CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy.

Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for this research and OncoHost.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.